This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): SCH 900395
Description: Acadesine (AICAR) is an investigational adenosine regulating agent (ARA). AICAR, a nucleoside widely used as AMPK activator, is converted inside the cell to its mono-phosphorylated form ZMP (5-amino-4-imidazolecarboxamide ribotide), and as such behaves as an AMP analogue capable of activating AMPK upstream of the tumor suppressor gene LKB1. AICAR mediated AMPK activation has been reported to inhibit cell proliferation and cell cycle progression via inhibition of the PI3K/Akt pathway and the cell cycle regulatory proteins p21, p27 and p53.
Deal Structure: Acadesine was originally developed by Metabasis.
In 2005, PeriCor sublicensed rights from Metabasis to acadesine and three additional Adenosine Regulating Agents.
In August 2007, PeriCor granted a license to Schering-Plough for global development and commercialization of acadesine for all indications. Financial terms of the transaction were not disclosed.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and Schering-Plough announced that their merger completed on November 3, 2009.
In October 2009, Ligand Pharmaceuticals and Metabasis Therapeutics...See full deal structure in Biomedtracker
Partners: Ligand Pharmaceuticals, Inc. PeriCor Therapeutics, Inc.
Additional information available to subscribers only: